Services & Technologies

Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO)

Agroaxis offers a comprehensive technological package to the manufacturing of lab and pilot-scale, phase I/II clinical trials and commercial-stage biopharmaceutical products, primary recombinant protein, by employing superior GMP compliant services that enable cost-effective. Agroaxis is able to perfom the complete development program or individual work package:

  • Proof of Concept
  • Assay Tech Transfer
  • Functional Assay :
    • Proliferation assay
    • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    • Complement-dependent cytotoxicity (CDC)
  • Structural
    • Charge Heterogeneity
    • Glycosylation profile
    • Aggregate content
  • Master / Working seed Bank
  • Plant Culture Process Development
  • Protein Purification
  • Engineering / Pilot Run
  • GMP Manufacturing for phase I/II clinical trials
  • Commercial production
  • Regulatory-compliant GMP facilities
  • Complete process R&D service offering



Logo Template - Logo_12 greenmab

GreenMab® is a self-developed, higher plant-based technological platform, that allows the optimized from lab to large scale production of biopharmaceutical proteins with a fully humanized post-translational modification (PTM) pattern. This concept uses the Vertical Greenhouse resulting the technological platform Vertical Greenhouse Pharming (VGP®) envisages the plant as a biofactory for the production of humanized proteins.

GreenMab® is technological platform that uses a tobacco plant (Nicotiana tabacum) that has been genetically modified to specifically produce therapeutic proteins and monoclonal antibodies, while growing hydroponically in greenhouses (licensed by AGROAXIS S.L.)

GreenMab® provides relevant advantages to the production of pharmaceutical proteins:

  • Low initial required investment and low production cost
  • Flexibility and ease of scale-up during production
  • No qualified staff is required
  • Improved product safety: GreenMab® is free of prions, viruses and other human or animal pathogens that could contaminate the final product
  • The final recombinant molecules display the human pattern of PTM

GreenMab® is a trade mark that belongs to Agroaxis

More on Agroaxis

The advances in molecular biology and more particularly recombinant DNA technology has allowed nutritionally valuable products, healthcare and industry , can be produced in large quantities at low cost and with increased biosafety.
The idea of using plant systems for the production of recombinant proteins has ceased to be a challenge to become a reality and alternative for the biopharmaceutical industry.

AGROAXIS decided to use and adapt the System NGS® to all their technology platforms to respond to the growing need of a new culture technologies and as a result of water scarcity and soil low yields increasingly overexploited.

Latest News

  • Agroaxis hires three more technologists with the grant Inncorpora TU of the Ministry of Economy and Competitiveness
  • Agroaxis creates the first GreenMab® technology platform with plants Snuff “Human “Insulin for obtaining

    Copyright 2013 Agroaxis. All Rights Reserved